MassChallenge has selected 10 Houston startups to participate in its 2022 United States cohort. Photo courtesy of MassChallenge

Ten Houston companies have been chosen for MassChallenge’s 2022 United States cohort of early-stage startups.

The 10 Houston startups are:

  • BEMY Cosmetics, a maker of skin rejuvenation products based on RNA technology
  • Eisana Corp., whose products are designed to ease the side effects of breast cancer treatment
  • Enrichly, a self-esteem-based e-learning platform and gaming app
  • RE.STATEMENT, an online marketplace for upcycled clothing
  • Roxie Health, a virtual medical assigned geared toward preventing falls by seniors
  • Vivifi Medical, whose laparoscopic technology treats male infertility and prostate gland enlargement
  • Vouchpad, a provider of affordable student loans
  • Equiliberty, an equitable fintech platform focused on creating generational wealth
  • National Police Data, an organization creating an index of Police data in America
  • Cryodesalination, a new low cost desalination process focused on providing access to fresh water

In all, the MassChallenge innovation network selected 250 early-stage startups for this fall’s U.S. accelerator program in Houston, Austin, Dallas, Boston, and Providence, Rhode Island. Participants are eligible for equity-free cash prizes of as much as $1 million. MassChallenge is open to early-stage startups that have raised less than $1 million in equity funding and have generated less than $2 million in revenue over the past 12 months.

“We’re in the business of solving massive challenges, and to do that, we must continue to support diverse founders with bold ideas across geographies, industry verticals, and demographics in creative ways that allow them to wholly own their ideas and solve some of our world’s most pressing problems,” Hope Hopkins, head of acceleration at MassChallenge, says in a news release.

This year’s cohort will have access to MassChallenge’s new residency program, which allows founder teams to travel to MassChallenge’s U.S.-based hubs. The residency program already is underway in Houston and Boston.

In addition, founders will be able to take advantage of a newly created program that enables them to connect with MassChallenge stakeholders.

Last year, MassChallenge named 71 startups to its Houston cohort, and several walked away from the program with cash prizes. Per the nonprofit's website, there isn't a Houston-specific program planned for 2022. MassChallenge has had a presence in Houston since January of 2019 when it announced the Bayou City as a new market.

Note: This article originally identified seven Houston startups. The article has been updated to include the three Houston startups initially omitted.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

TMC launches new biotech partnership with Republic of Korea

international collaboration

Houston's Texas Medical Center has launched its new TMC Republic of Korea BioBridge.

The new partnership brings together the TMC with the Osong Medical Innovation Foundation, or KBIOHealth. The Biobridge aims to support the commercialization of Korean biotech and life science startups in the U.S., foster clinical research, and boost collaboration in the public, private and academic sectors.

Through the partnership, TMC will also develop a Global Innovators Launch Pad to foster U.S. market entry for international health care companies. Founders will be selected to participate in the 10-week program at the TMC Innovation Factory in Houston.

“Gene and cell therapies are driving biotech innovation, opening possibilities for treating diseases once thought untreatable," William McKeon, president and CEO of the Texas Medical Center, said in a news release. "Expanding biomanufacturing capacity is essential to delivering the next wave of these therapies, and partnerships with leading innovators will strengthen our efforts in Houston and internationally.”

McKeon officially signed the TMC Korea BioBridge Memorandum of Understanding with Myoung Su Lee, chairman of KBIOHealth, in South Korea in October.

"This collaboration marks a significant milestone for Korea’s biohealth ecosystem, creating a powerful bridge between Osong and Houston," Lee added in the release. "By combining KBIOHealth’s strength in research infrastructure and Korea’s biotech talent with TMC’s global network and accelerator platform, we aim to accelerate innovation and bring transformative solutions to patients worldwide.”

This is the seventh international strategic partnership for the TMC. It launched its first BioBridge with the Health Informatics Society of Australia in 2016. It launched its TMC Japan BioBridge, focused on advancing cancer treatments, last year. It also has BioBridge partnerships with the Netherlands, Ireland, Denmark and the United Kingdom.